Literature DB >> 15245363

Antihistamines: do they work? Further well-controlled trials involving larger samples are needed.

F Fumagalli1, I Baiardini, M Pasquali, E Compalati, L Guerra, P Massacane, G W Canonica.   

Abstract

Histamine is one of the most important steps in the phlogistic allergic reaction. Its activity is due to the link to specific receptors on the cellular surface. H1-receptors of second generation are the most currently prescribed drugs in allergic diseases for their high selectivity, little or no central sedative effect, rapid onset of action and long half lives. Antihistamines can modulate part of immunological mechanisms involved in the pathogenesis of allergic inflammation reducing mediator release and expression of adhesion molecules, regulating the release of cytokines, chemokines and consequently inflammatory cells recruitment. The anti-inflammatory effects of cetirizine, desloratadine and levocetirizine are reviewed. Quality of life is considered too, as a main parameter in a global evaluation of the antihistamine's effects. Copyright 2004 Blackwell Munksgaard

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15245363     DOI: 10.1111/j.1398-9995.2004.00573.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  3 in total

1.  Histamine H₂ receptor signaling × environment interactions determine susceptibility to experimental allergic encephalomyelitis.

Authors:  Naresha Saligrama; Laure K Case; Dimitry N Krementsov; Cory Teuscher
Journal:  FASEB J       Date:  2013-12-26       Impact factor: 5.191

2.  A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled study.

Authors:  Kf Lukat; P Rivas; A Roger; Ml Kowalski; U Botzen; F Wessel; F Sanquer; I Agache; I Izquierdo
Journal:  J Asthma Allergy       Date:  2013-02-22

3.  Management of persistent allergic rhinitis: evidence-based treatment with levocetirizine.

Authors:  Joaquim Mullol; Claus Bachert; Jean Bousquet
Journal:  Ther Clin Risk Manag       Date:  2005-12       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.